Recent News

• 03.27.2026 - Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
• 03.24.2026 - Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
• 03.12.2026 - Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
• 03.06.2026 - Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
• 02.13.2026 - Intensity Therapeutics Announces Reverse Stock Split
• 01.13.2026 - Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
• 12.11.2025 - Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
• 12.05.2025 - Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Recent Filings

• 03.23.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.23.2026 - 8-K Current report
• 03.06.2026 - EX-99.1 EX-99.1
• 03.06.2026 - 8-K Current report
• 03.05.2026 - 8-K Current report
• 03.05.2026 - EX-99.1 EX-99.1
• 02.13.2026 - 8-K Current report
• 02.13.2026 - EX-99.1 EX-99.1
• 01.23.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities